11 completed. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 1 | 1 | Completed 1 |
Follow Urinary Incontinence, Urge: new trials by email Literature Review of Urinary Incontinence, Urge trials Research Report on Urinary Incontinence, Urge
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lidocaine Patches Prior to Percutaneous Nerve Evaluation Lidocaine patch, Placebo - Overactive Bladder, Urge Incontinence | Phase 2 | Completed | University of Louisville | 39 | 2023-05-01 | 2025-02-03 |
| URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence URO-902, Placebo - Overactive Bladder With Urge Urinary Incontinence | Phase 2 | Completed | Urovant Sciences GmbH | 80 | 2019-12-16 | 2023-04-20 |
| Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence UISH001, matching placebo - Urinary Incontinence | Phase 1 / Phase 2 | Completed | Beech Tree Labs, Inc. | 94 | 2011-04-01 | 2013-05-03 |
| Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency AOBO-001, Placebo - Overactive Bladder | Phase 2 | Completed | American Oriental Bioengineering, Inc. | 66 | 2010-12-01 | 2013-01-23 |
| Translating Unique Learning for Incontinence Prevention Instructional DVD, Bladder Health Class - Urinary Incontinence | Phase 2 | Completed | University of Michigan | 647 | 2010-09-01 | 2016-05-12 |
| SSR240600C Treatment in Women With Overactive Bladder SSR240600C, tolterodine, placebo - Overactive Bladder | Phase 2 | Completed | Sanofi | 345 | 2007-11-01 | 2016-05-26 |
| A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence oxybutynin - Urinary Incontinence, Urge | Phase 2 | Completed | FemmePharma Global Healthcare, Inc. | 45 | 2007-07-01 | 2009-10-15 |
| Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. Botulinum Toxin A (Botox ) - Overactive Bladder | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 160 | 2005-11-01 | 2011-02-17 |
| Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder DR-3001a, DR-3001b, Placebo - Urinary Incontinence | Phase 2 | Completed | Duramed Research | 800 | 2004-10-01 | 2012-08-20 |
| Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder YM178, tolterodine, Placebo - Urinary Bladder, Overactive | Phase 2 | Completed | Astellas Pharma Europe B.V. | 260 | 2004-04-05 | 2024-10-31 |
| A Phase II Study of KUC-7483 in Patients With Overactive Bladder KUC-7483, Placebo - Overactive Bladder (OAB) | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 400 | 2009-09-04 |
Urinary Bladder, Overactive (9) · Urinary Incontinence (5) · Urinary Incontinence, Stress (2) · Fecal Incontinence (1) · Nocturnal Enuresis (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Lower Urinary Tract Symptoms (11) · Male Urogenital Diseases (11) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Urination Disorders (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Urological Manifestations (11) · Urinary Bladder Diseases (9) · Urinary Incontinence (6) · Behavior (1) · Behavioral Symptoms (1) · Digestive System Diseases (1)
Tolterodine Tartrate (2) · Botulinum Toxins, Type A (1) · mirabegron (1) · oxybutynin (1) · ritobegron ethyl (1)
American Oriental Bioengineering, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Europe B.V. (1) · Beech Tree Labs, Inc. (1) · Duramed Research (1) · FemmePharma Global Healthcare, Inc. (1) · Kissei Pharmaceutical Co., Ltd. (1) · Sanofi (1) · University of Louisville (1) · University of Michigan (1) · Urovant Sciences GmbH (1)
United States (8) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Belgium (1) · Japan (1) · Netherlands (1) · Portugal (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Carolyn Sampselle, PHD, RN (1) · Hanh Badger, PharmD (1) · Peter K. Mays, Ph.D. (1) · Tom Du, MD, PhD (1) · Yasuhiro Omori (1)
PMID 22036776, PMID 23424164, PMID 37160401, PMID 40013530
R01NR012011 (1)